Back to Authors

Klements, David

https://orcid.org/0000-0002-3391-6010

A5051521501 | I4210087915

Mayo Clinic

Massachusetts General Hospital

Citations 5

The ExTINGUISH Modified Rankin Scale: A Comprehensive Functional Outcome Measure for NMDAR Encephalitis (P8-1.005)

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216310

A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH Trial

Neurology Open Access | April 25, 2025 | Volume: 1 | Issue: 2 | Pages: No page available

10.1212/wn9.0000000000000007 | PMID 40625668

The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis (P5-1.004)

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.1651

Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression

JAMA | September 14, 2021 | Volume: 326 | Issue: 10 | Pages: 926

10.1001/jama.2021.10207 | PMID 34519802

Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis

JAMA Neurology | November 23, 2020 | Volume: 78 | Issue: 2 | Pages: 186

10.1001/jamaneurol.2020.4300 | PMID 33226425